Database : MEDLINE
Search on : Arteriosclerosis and Obliterans [Words]
References found : 3673 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 368 go to page                         

  1 / 3673 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29258125
[Au] Autor:Heim C; Gocht A; Weyand M; Ensminger S
[Ad] Address:Department of Cardiac Surgery, University of Erlangen-Nuremberg, Erlangen, Germany.
[Ti] Title:New Targets for the Prevention of Chronic Rejection after Thoracic Organ Transplantation.
[So] Source:Thorac Cardiovasc Surg;66(1):20-30, 2018 01.
[Is] ISSN:1439-1902
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:The gold standard for the treatment of terminal heart failure and irreversible lung diseases includes thoracic organ transplantation. The major obstacle for long-term survival after successful transplantation is chronic rejection, an ongoing immunomodulatory disease so far without effective therapy. Therefore, the aim of this review is to elucidate scientific efforts targeting different new mechanisms of cardiac allograft vasculopathy (CAV) and chronic lung allograft dysfunction (CLAD). For this purpose, we performed a systematic review of the literature to assess recent strategies in transplant immunology research. We searched MEDLINE from 2015 up to date for articles addressing the following keywords: CAV, transplant vasculopathy, transplant arteriosclerosis, CLAD, bronchiolitis obliterans transplant, and obliterative bronchiolitis transplant. All articles including experimental models in the field of transplant immunology addressing new aspects for the prevention of chronic rejection after heart and lung transplantation were included in this review. The prevention of chronic rejection would clearly improve the survival of patients after heart and lung transplantation. Interesting targets were addressed in recent research, but further research is necessary to effectively treat this life-threatening disease in transplant recipients.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Process
[do] DOI:10.1055/s-0037-1615290

  2 / 3673 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29386474
[Au] Autor:Kondo K; Yanishi K; Hayashida R; Shintani S; Shibata R; Murotani K; Ando M; Mizuno M; Fujiwara T; Murohara T; Matoba S; TACT Follow-up Study Investigators
[Ad] Address:Department of Cardiology, Nagoya University Graduate School of Medicine.
[Ti] Title:Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan.
[So] Source:Circ J;, 2018 Jan 30.
[Is] ISSN:1347-4820
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:BACKGROUND: The Therapeutic Angiogenesis by Cell Transplantation (TACT) trial demonstrated the efficacy and safety of autologous bone marrow-derived mononuclear cells (BM-MNCs) in patients with critical limb ischemia (CLI). The present study aimed to assess the long-term clinical outcomes of therapeutic angiogenesis using autologous BM-MNC implantation under advanced medical treatment in Japan.Methods and Results:The study was retrospective, observational, and non-controlled. We assessed no-option CLI patients who had BM-MNC implantation performed in 10 institutes. Overall survival (OS), major amputation-free (MAF), and amputation-free survival (AFS) rates were primary endpoints of this study. The median follow-up duration was 31.7 months. The 10-year OS rate was 46.6% in patients with arteriosclerosis obliterans (ASO) (n=168), 90.5% in patients with thromboangiitis obliterans (TAO) (n=108), and 67.6% in patients with collagen disease-associated vasculitis (CDV) (n=69). The 10-year MAF rate was 70.1%, 87.9%, and 90.9%, respectively. The 10-year AFS rate was 37.8%, 80.9%, and 61.2%, respectively. Major adverse cardiovascular events occurred in 6.0% of patients with ASO, 1.9% of patients with TAO, and no patients with CDV. CONCLUSIONS: Therapeutic angiogenesis using autologous BM-MNC implantation may be feasible and safe in patients with no-option CLI, particularly those with CLI caused by TAO or CDV.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180201
[Lr] Last revision date:180201
[St] Status:Publisher
[do] DOI:10.1253/circj.CJ-17-0510

  3 / 3673 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29057733
[Au] Autor:Yahata K; Kikuchi Y; Koizumi M; Seta K; Wakui H; Komatsuda A; Shimizu A
[Ti] Title:Membranoproliferative glomerulonephritis with unusual deposits of parallel arrangement striated structure: a new pathological entity?
.
[So] Source:Clin Nephrol;, 2017 Oct 23.
[Is] ISSN:0301-0430
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:A 71-year-old male with a past history of lower limb arteriosclerosis obliterans developed nephrotic syndrome and renal dysfunction. Renal biopsy showed diffuse global endocapillary proliferative lesions with infiltration of mononuclear cells and occasional foam cells. An irregular double contour of the glomerular basement membrane and global mild-to-moderate mesangial proliferative lesions were observed, indicating membranoproliferative glomerulonephritis. Congo red staining was negative. Routine immunofluorescence studies showed no obvious immunoglobulin or complement depositions. Electron microscopy showed endocapillary proliferative lesions and infiltration of macrophages with abundant lysosomes. Irregular subepithelial, subendothelial, and mesangial electron-dense deposits were observed in glomeruli. In these electron-dense deposits, parallel arrangement striated structures were detected. All known disease entities with Congo red-negative and immunoglobulin-negative glomerular deposits were pathologically excluded. The glomerular lesion in our case might be a new disease entity.
.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171025
[Lr] Last revision date:171025
[St] Status:Publisher
[do] DOI:10.5414/CN109169

  4 / 3673 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28965798
[Au] Autor:Kikuchi S; Sasajima T; Inaba M; Uchida D; Kokubo T; Saito Y; Koya A; Uchida H; Azuma N
[Ad] Address:Department of Vascular Surgery, Asahikawa Medical University, Asahikawa, Japan.
[Ti] Title:Evaluation of paramalleolar and inframalleolar bypasses in dialysis- and nondialysis-dependent patients with critical limb ischemia.
[So] Source:J Vasc Surg;, 2017 Sep 28.
[Is] ISSN:1097-6809
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: The aim of this study was to elucidate the efficacy of paramalleolar or inframalleolar bypass (PIMB) in hemodialysis-dependent (HD) patients with critical limb ischemia (CLI) and nonhemodialysis-dependent (NHD) patients in terms of clinical outcomes. METHODS: Between January 2000 and December 2013, there were 333 consecutive arteriosclerosis obliterans patients with CLI who underwent 401 PIMB procedures for limb salvage (LS). Of the 333 patients, 188 (56.5%) were HD patients. Vein grafts were exclusively used, and 172 paramalleolar and 229 inframalleolar bypasses were performed. Five-year primary and secondary cumulative graft patency, LS, and amputation-free survival (AFS) rates were compared between the two groups, and the independent determinants of these outcomes were identified in each group. RESULTS: The 5-year primary and secondary cumulative graft patency rates were 53% and 82% in HD patients and 69% and 92% in NHD patients (primary cumulative graft patency, P< .05; secondary cumulative graft patency, nonsignificant), respectively. The LS rates were 87% and 99% (P< .01) in HD patients and NHD patients, respectively. Overall, 48% and 70% of HD and NHD patients were ambulatory before PIMB (P< .01), and 73% and 85% of HD and NHD patients were ambulatory 12months after PIMB (including 1-year survivors; nonsignificant), respectively, demonstrating drastic post-PIMB improvement in HD patients. The 5-year AFS rates in the HD and NHD groups were 27% and 69% (P< .01), respectively, demonstrating very poor AFS rates in HD patients. In HD patients, factors negatively associated with AFS were female gender (hazard ratio [HR], 2.102; 95% confidence interval [CI], 1.254-3.524), history of congestive heart failure (HR, 2.075; 95% CI, 1.395-3.085), and preoperative nonambulatory status (HR, 1.974; 95% CI, 1.305-2.986), whereas older age (HR, 2.601; 95% CI, 1.372-4.931) and history of congestive heart failure (HR, 2.928; 95% CI, 1.496-5.731) were identified as independent factors negatively associated with AFS in NHD patients. CONCLUSIONS: The use of PIMB for CLI was associated with excellent LS rates in both HD and NHD patients with low operative mortality and complications. However, the AFS rate observed in HD patients was significantly lower than that observed in NHD patients, indicating the necessity of a specific management program to improve AFS after LS in HD patients.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171002
[Lr] Last revision date:171002
[St] Status:Publisher

  5 / 3673 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28864202
[Au] Autor:Sun XL; Law BY; de Seabra Rodrigues Dias IR; Mok SWF; He YZ; Wong VK
[Ad] Address:State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China; Department of Vascular and Thyroid Surgery of the Affiliated Hospital of Southwest Medical University, Sichuan Province, China.
[Ti] Title:Pathogenesis of thromboangiitis obliterans: Gene polymorphism and immunoregulation of human vascular endothelial cells.
[So] Source:Atherosclerosis;265:258-265, 2017 Oct.
[Is] ISSN:1879-1484
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:Thromboangiitis obliterans (TAO) is a nonatherosclerotic, segmental, inflammatory vasculitis, which commonly affects the small- and medium-sized arteries of the upper and lower extremities. Despite its discovery more than a century ago, little progress has been made in its treatment. Unless the pathogenesis is elucidated, therapeutic approaches will be limited. The purpose of this review article is to collate current knowledge of mechanisms for the pathogenesis of thromboangiitis obliterans and to propose potential mechanisms from a genetic and immunoreactive point of view for its inception. Therefore, we discuss the possibility that the pathogenesis of this disease is due to a type of gene polymorphism, which leads to an immunological inflammatory vasculitis associated with tobacco abuse, highly linked to T cells, human vascular endothelial cells (HVECs), and the TLR-MyD88-NFκB pathway, distinct from arteriosclerosis obliterans and other vasculitides.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1709
[Cu] Class update date: 170927
[Lr] Last revision date:170927
[St] Status:In-Process

  6 / 3673 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28848136
[Au] Autor:Huang SC; Wang M; Wu WB; Wang R; Cui J; Li W; Li ZL; Li W; Wang SM
[Ad] Address:Department of Vascular Surgery, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
[Ti] Title:Mir-22-3p Inhibits Arterial Smooth Muscle Cell Proliferation and Migration and Neointimal Hyperplasia by Targeting HMGB1 in Arteriosclerosis Obliterans.
[So] Source:Cell Physiol Biochem;42(6):2492-2506, 2017.
[Is] ISSN:1421-9778
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:BACKGROUND: Aberrant vascular smooth muscle cell (VSMC) proliferation and migration contribute to the development of vascular pathologies, such as atherosclerosis and post-angioplasty restenosis. The aim of this study was to determine whether miR-22-3p plays a role in regulating human artery vascular smooth muscle cell (HASMC) function and neointima formation. METHODS: Quantitative real-time PCR (qRT-PCR) and fluorescence in situ hybridization (FISH) were used to detect miR-22-3p expression in human arteries. Cell Counting Kit-8 (CCK-8) and EdU assays were performed to assess cell proliferation, and transwell and wound closure assays were performed to assess cell migration. Moreover, luciferase reporter assays were performed to identify the target genes of miR-22-3p. Finally, a rat carotid artery balloon-injury model was used to determine the role of miR-22-3p in neointima formation. RESULTS: MiR-22-3p expression was downregulated in arteriosclerosis obliterans (ASO) arteries compared with normal arteries, as well as in platelet-derived growth factor-BB (PDGF-BB)-stimulated HASMCs compared with control cells. MiR-22-3p overexpression had anti-proliferative and anti-migratory effects and dual-luciferase assay showed that high mobility group box-1 (HMGB1) is a direct target of miR-22-3p in HASMCs. Furthermore, miR-22-3p expression was negatively correlated with HMGB1 expression in ASO tissue specimens. Finally, LV-miR-22-3p-mediated miR-22-3p upregulation significantly suppressed neointimal hyperplasia specifically by reducing HMGB1 expression in vivo. CONCLUSIONS: Our results indicate that miR-22-3p is a key molecule in regulating HASMC proliferation and migration by targeting HMGB1 and that miR-22-3p and HMGB1 may be therapeutic targets in the treatment of human ASO.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1708
[Cu] Class update date: 171017
[Lr] Last revision date:171017
[St] Status:In-Process
[do] DOI:10.1159/000480212

  7 / 3673 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28768953
[Au] Autor:Hosono T; Kondo A; Kambayashi Y; Homma M
[Ad] Address:Pharmacy Department, University of Tsukuba Hospital.
[Ti] Title:Effects of Tramadol Coadministration on Prothrombin Time-International Normalized Ratio in Patients Receiving Warfarin.
[So] Source:Yakugaku Zasshi;137(8):999-1003, 2017.
[Is] ISSN:1347-5231
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:Several case studies have reported a possible drug interaction between warfarin and tramadol where tramadol coadministration enhanced the antithrombotic effects of warfarin. To assess this drug interaction, changes in prothrombin time-international normalized ratio (PT-INR) before and after tramadol coadministration were investigated in patients receiving warfarin. For this study, we examined 54 patients (male/female: 22/32, 68.412.7 years) who were being treated with warfarin for deep vein thrombosis, atrial fibrillation, arteriosclerosis obliterans, congestive heart failure, and other vascular diseases. Significant increases in PT-INR were observed 9.5 (1-118) d after coadministration of tramadol (1.810.56 vs. 2.471.10, p<0.01). Twenty-eight patients (PT-INR increased group) with PT-INR elevation of greater than 0.5 or dose reduction of warfarin after coadministration of tramadol were compared with other groups of patients to find drug interaction risk factors. Logistic regression analysis revealed that lower levels of albumin (3.5 g/dL or less) [odds ratio (OR) 22.1; 95%CI 2.9-169.9]; lower eGFR (50 mL/min or less) (OR 7.7; 95%CI 1.4-42.0); and PT-INR before tramadol coadministration (OR 38.2; 95%CI 3.7-397.6) were characteristic of the PT-INR increased group. These results suggest that tramadol coadministration enhanced the antithrombotic effects of warfarin in patients with higher PT-INR, lower albumin levels and decreased renal function as the risk factors for this drug interaction.
[Mh] MeSH terms primary: Fibrinolytic Agents/administration & dosage
Fibrinolytic Agents/pharmacology
International Normalized Ratio
Prothrombin Time
Tramadol/administration & dosage
Tramadol/pharmacology
Warfarin/administration & dosage
Warfarin/pharmacology
[Mh] MeSH terms secundary: Aged
Aged, 80 and over
Cardiovascular Diseases/drug therapy
Drug Interactions
Drug Synergism
Drug Therapy, Combination
Female
Glomerular Filtration Rate
Humans
Logistic Models
Male
Middle Aged
Risk Factors
Serum Albumin/metabolism
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Fibrinolytic Agents); 0 (Serum Albumin); 39J1LGJ30J (Tramadol); 5Q7ZVV76EI (Warfarin)
[Em] Entry month:1710
[Cu] Class update date: 171030
[Lr] Last revision date:171030
[Js] Journal subset:IM
[Da] Date of entry for processing:170804
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.16-00270

  8 / 3673 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28767168
[Au] Autor:Tanaka K; Igari K; Kishino M; Usami S; Homma T; Toyofuku T; Inoue Y; Okazaki M
[Ad] Address:Department of Plastic and Reconstructive Surgery, Graduate School of Medical Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
[Ti] Title:The possibility of free tissue transfer as a nutrient flap for critical ischemic foot: A case report.
[So] Source:Microsurgery;37(6):694-698, 2017 Sep.
[Is] ISSN:1098-2752
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Microsurgical procedure of free tissue transfer in critical limb ischemia patients with large ulceration has already been established. The nutrient flap concept was that transferred tissue functioned not only to cover the skin defect but also as a supplementary blood supply to the ischemic lower leg. This report showed the justification for this concept, which was rarely discussed. A 58-year-old male patient with progressive forefoot gangrene caused by arteriosclerosis obliterans was presented. The distal bypass procedure was performed as revascularization surgery, and a latissimus dorsi (LD) myocutaneous flap was transplanted to cover ulceration. The arterial pedicle of the flap was anastomosed to the vein graft in an end-to-end manner, and the venous pedicle was anastomosed to the posterior tibialis vein in an end-to-end manner. Bypass graft blood flow went straight to the LD flap only. The postoperative course was uneventful. The free flap and right foot survived successfully and the patient was ambulatory with no recurrence of ulceration wearing order-made shoes more than three years after transplantation. Vessel-selective angiography was performed two months after surgery. An angiographic catheter was inserted into the bypass graft, which ran straight through the flap nutrient artery. The results obtained showed that not only the transferred flap area, but also the remaining original foot soft tissue (including the sole and heel) was clearly visualized radiologically only through the flap nutrient vessel. This findings of the angiography appear to provide direct evidence for the nutrient flap concept.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1708
[Cu] Class update date: 170923
[Lr] Last revision date:170923
[St] Status:In-Process
[do] DOI:10.1002/micr.30215

  9 / 3673 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28733607
[Au] Autor:Higashi Y; Miyata T; Shigematsu H; Origasa H; Fujita M; Matsuo H; Naritomi H; Matsuda H; Nakajima M; Awano H
[Ad] Address:Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. yhigashi@hiroshima-u.ac.jp.
[Ti] Title:Two-Year Follow-Up of Vascular Events in Peripheral Arterial Disease Treated With Antiplatelet Agents: A Prospective Observational Multicenter Cohort Study (SEASON).
[So] Source:Sci Rep;7(1):6095, 2017 Jul 21.
[Is] ISSN:2045-2322
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The present analysis was intended to evaluate the real-world management of peripheral arterial disease (PAD) in Asia, and to explore cardiovascular events in patients with PAD undergoing antiplatelet therapy over 2 years of follow-up. The Surveillance of cardiovascular Events in Antiplatelet-treated arteriosclerosis Obliterans patients in JapaN (SEASON) registry is a prospective observational multicenter study of cardiovascular events in antiplatelet-treated patients with PAD in Japan. The SEASON registry included 11,375 patients who were scheduled to receive treatment for PAD. Two analysis populations were defined: a real-world population (RWP; n = 10,322) and a definite PAD population (DPP; n = 3992) who had ankle-brachial pressure index (ABPI) <0.9 and intermittent claudication, or a history of lower limb revascularization. The primary outcome measure was the rate of the composite of cerebrovascular, cardiovascular, and peripheral vascular events. The composite event rates (95% confidence interval) were 3.28 (3.00-3.57) and 5.71 (5.13-6.34) events per 100 patient-years in the RWP and DPP groups, respectively. Fontaine IV classification and ABPI <0.4 at baseline were both identified as strong risk factors for vascular events. These findings contribute to understanding the situation for real-world patients with PAD receiving antiplatelet therapy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1707
[Cu] Class update date: 170727
[Lr] Last revision date:170727
[St] Status:In-Data-Review
[do] DOI:10.1038/s41598-017-06597-y

  10 / 3673 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28629476
[Au] Autor:Darinskas A; Paskevicius M; Apanavicius G; Vilkevicius G; Labanauskas L; Ichim TE; Rimdeika R
[Ad] Address:Laboratory of Immunology, National Cancer Institute, Santariskiu Str. 1, 08660, Vilnius, Lithuania. darinskas.adas@gmail.com.
[Ti] Title:Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study.
[So] Source:J Transl Med;15(1):143, 2017 Jun 19.
[Is] ISSN:1479-5876
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Cell-based therapy is being explored as an alternative treatment option for critical limb ischemia (CLI), a disease associated with high amputation and mortality rates and poor quality of life. However, therapeutic potential of uncultured adipose-derived stromal vascular fraction (SVF) cells has not been evaluated as a possible treatment. In this pilot study, we investigated the efficacy of multiple injections of autologous uncultured adipose-derived SVF cells to treat patients with CLI. METHODS: This study included 15 patients, from 35 to 77years old, with rest pain and ulceration. SVF cells were injected once or twice in the ischemic limb along the arteries. Digital subtraction angiography was performed before and after cell therapy. The clinical follow up was carried out for the subsequent 12months after the beginning of the treatment. RESULTS: Multiple intramuscular SVF cell injections caused no complications during the follow-up period. Clinical improvement occurred in 86.7% of patients. Two patients required major amputation, and the amputation sites healed completely. The rest of patients achieved a complete ulcer healing, pain relief, improved ankle-brachial pressure index and claudication walking distance, and had ameliorated their quality of life. Digital subtraction angiography performed before and after SVF cell therapy showed formation of numerous vascular collateral networks across affected arteries. CONCLUSION: Results of this pilot study demonstrate that the multiple intramuscular SVF cell injections stimulate regeneration of injured tissue and are effective alternative to achieve therapeutic angiogenesis in CLI patients who are not eligible for conventional treatment. Trial registration number at ISRCTN registry, ISRCTN13001382. Retrospectively registered at 26/04/2017.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1706
[Cu] Class update date: 170624
[Lr] Last revision date:170624
[St] Status:In-Process
[do] DOI:10.1186/s12967-017-1243-3


page 1 of 368 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information